The acquisition is part of a strategic collaboration where the companies will strengthen their offerings in documentation, clinical studies, and data analysis for the aquaculture industry.
Powered by deep expertise and experience
Salmalytics was established in 2020 and consists of professionals with backgrounds in veterinary medicine, biology, epidemiology, and aquaculture expertise. The company assists fish farmers, suppliers, and technology developers with study design, conducting trials, analysis, and models for decision support.
“The partnership gives us the opportunity to further develop our services, while maintaining our own organization and way of working”, says Arnfinn Aunsmo, Managing Director of Salmalytics.
Complementary Competence
VESO is an established player in fish health and veterinary medicine and, among other things, conducts contract research, product documentation, and regulatory consulting through VESO Aqualab.
“Salmalytics has expertise that complements our services and gives us better conditions for comprehensive deliveries, especially within clinical studies and statistical calculations”, says Bjørn Skjævestad, CEO of VESO.
Joint Efforts Going Forward
The companies will collaborate to further develop their services. Both companies represent environments with strong professional competence combined with long experience and insight into the challenges facing the aquaculture industry. The goal is to offer more integrated and efficient processes for customers.
The acquisition took effect on November 24th 2025.
About VESO
VESO delivers veterinary products, infection control solutions, and research and development services, as well as regulatory consulting and contract research to players in the global aquaculture industry.
About Salmalytics
Salmalytics is a professional consultant company established in 2020 that delivers study design, data collection, statistical analysis, and decision support models for players in the seafood industry.
